Loading...
Curaleaf Holdings, Inc.
CURLF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.44
$0.17(13.39%)
Curaleaf Holdings, Inc. (CURLF) Financial Performance & Income Statement Overview
Review Curaleaf Holdings, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-0.28%
↓ 0.28%
Operating Income Growth
-52.90%
↓ 52.90%
Net Income Growth
23.39%
↑ 23.39%
Operating Cash Flow Growth
116.008%
↑ 116.008%
Operating Margin
1.17%
↑ 1.17%
Gross Margin
45.43%
↑ 45.43%
Net Profit Margin
-18.19%
↓ 18.19%
ROE
-24.96%
↓ 24.96%
ROIC
0.60%
↑ 0.60%
Curaleaf Holdings, Inc. (CURLF) Income Statement & Financial Overview
Review Curaleaf Holdings, Inc.'s (CURLF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $331.05M | $330.53M | $342.22M | $337.42M |
| Cost of Revenue | $173.69M | $170.01M | $218.34M | $213.37M |
| Gross Profit | $157.36M | $160.52M | $123.87M | $124.05M |
| Gross Profit Ratio | $0.48 | $0.49 | $0.36 | $0.37 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $118.08M | $109.23M | $116.33M | $111.40M |
| Operating Expenses | $166.64M | $151.29M | $116.33M | $111.40M |
| Total Costs & Expenses | $340.33M | $321.30M | $334.74M | $324.77M |
| Interest Income | $171033.00 | $274000.00 | $310000.00 | $17000.00 |
| Interest Expense | $24.35M | $25.37M | $25.12M | $25.78M |
| Depreciation & Amortization | $78.95M | $57.68M | $51.78M | $57.008M |
| EBITDA | $25.33M | $71.27M | $59.33M | $64.65M |
| EBITDA Ratio | $0.08 | $0.22 | $0.17 | $0.19 |
| Operating Income | -$9.28M | $9.23M | $7.55M | $12.65M |
| Operating Income Ratio | -$0.03 | $0.03 | $0.02 | $0.04 |
| Other Income/Expenses (Net) | -$67.95M | -$21.01M | -$24.71M | -$24.19M |
| Income Before Tax | -$77.23M | -$11.78M | -$17.16M | -$11.44M |
| Income Before Tax Ratio | -$0.23 | -$0.04 | -$0.05 | -$0.03 |
| Income Tax Expense | -$5.45M | $32.57M | $31.38M | $39.91M |
| Net Income | -$88.37M | -$40.70M | -$48.88M | -$48.10M |
| Net Income Ratio | -$0.27 | -$0.12 | -$0.14 | -$0.14 |
| EPS | -$0.10 | -$0.05 | -$0.07 | -$0.07 |
| Diluted EPS | -$0.10 | -$0.05 | -$0.07 | -$0.07 |
| Weighted Avg Shares Outstanding | $742.54M | $742.54M | $740.79M | $736.15M |
| Weighted Avg Shares Outstanding (Diluted) | $742.54M | $742.54M | $740.79M | $736.15M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan